

Jonathan B Gubbay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7193725/publications.pdf>

Version: 2024-02-01

157
papers

7,485
citations

87888

38
h-index

64796

79
g-index

161
all docs

161
docs citations

161
times ranked

12303
citing authors

#	ARTICLE	IF	CITATIONS
1	Influenza Vaccine Effectiveness by A(H3N2) Phylogenetic Subcluster and Prior Vaccination History: 2016–2017 and 2017–2018 Epidemics in Canada. <i>Journal of Infectious Diseases</i> , 2022, 225, 1387-1398.	4.0	18
2	Adverse Outcomes Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant B.1.351 Infection in Vaccinated Residents of a Long-Term Care Home, Ontario, Canada. <i>Clinical Infectious Diseases</i> , 2022, 74, 751-752.	5.8	14
3	Impact of coronavirus disease 2019 (COVID-19) pre-test probability on positive predictive value of high cycle threshold severe acute respiratory coronavirus virus 2 (SARS-CoV-2) real-time reverse transcription polymerase chain reaction (RT-PCR) test results. <i>Infection Control and Hospital Epidemiology</i> , 2022, 43, 1179-1183.	1.8	4
4	Effect of maternal vitamin D supplementation on nasal pneumococcal acquisition, carriage dynamics and carriage density in infants in Dhaka, Bangladesh. <i>BMC Infectious Diseases</i> , 2022, 22, 52.	2.9	0
5	Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. <i>Nature Microbiology</i> , 2022, 7, 379-385.	13.3	194
6	Real-Time RT-PCR Allelic Discrimination Assay for Detection of N501Y Mutation in the Spike Protein of SARS-CoV-2 Associated with B.1.1.7 Variant of Concern. <i>Microbiology Spectrum</i> , 2022, 10, e0068121.	3.0	5
7	Population immunity to measles in Canada using Canadian Health Measures survey data – A Canadian Immunization Research Network (CIRN) study. <i>Vaccine</i> , 2022, 40, 3228-3235.	3.8	3
8	S-Gene Target Failure as a Marker of Variant B.1.1.7 Among SARS-CoV-2 Isolates in the Greater Toronto Area, December 2020 to March 2021. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 2115.	7.4	102
9	Practical guidance for clinical laboratories for SARS-CoV-2 serology testing. <i>Canada Communicable Disease Report</i> , 2021, 47, 171-183.	1.3	12
10	Investigation of a severe SARS-CoV-2 outbreak in a long-term care home early in the pandemic. <i>Cmaj</i> , 2021, 193, E681-E688.	2.0	14
11	One swab, two tests: validation of dual SARS-CoV-2 testing on the Abbott ID NOW [®] . <i>Journal of Clinical Virology</i> , 2021, 141, 104896.	3.1	3
12	Surveilling and Tracking COVID-19 Patients Using a Portable Quantum Dot Smartphone Device. <i>Nano Letters</i> , 2021, 21, 5209-5216.	9.1	38
13	Beyond flu: Trends in respiratory infection outbreaks in Ontario healthcare settings from 2007 to 2017, and implications for non-influenza outbreak management. <i>Canada Communicable Disease Report</i> , 2021, 47, 269-275.	1.3	3
14	Duration of SARS-CoV-2 shedding: A population-based, Canadian study. <i>PLoS ONE</i> , 2021, 16, e0252217.	2.5	13
15	Effects of Maternal Vitamin D Supplementation During Pregnancy and Lactation on Infant Acute Respiratory Infections: Follow-up of a Randomized Trial in Bangladesh. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 901-909.	1.3	4
16	Characteristics of SARS-CoV-2 testing for rapid diagnosis of COVID-19 during the initial stages of a global pandemic. <i>PLoS ONE</i> , 2021, 16, e0253941.	2.5	3
17	Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study. <i>BMJ</i> , The, 2021, 374, n1943.	6.0	245
18	Surveillance for Common Arboviruses in Whole Blood of Malaria-Free Ill Returned Canadian Travelers to the Americas. <i>Current Infectious Disease Reports</i> , 2021, 23, 1.	3.0	0

#	ARTICLE	IF	CITATIONS
19	The impact of the COVID-19 pandemic on influenza, respiratory syncytial virus, and other seasonal respiratory virus circulation in Canada: A population-based study. <i>The Lancet Regional Health Americas</i> , 2021, 1, 100015.	2.6	100
20	Evaluation of commercial SARS-CoV-2 serological assays in Canadian public health laboratories. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 101, 115412.	1.8	10
21	Prevalence of Co-Infections with Respiratory Viruses in Individuals Investigated for SARS-CoV-2 in Ontario, Canada. <i>Viruses</i> , 2021, 13, 130.	3.3	26
22	Influenza Vaccine Effectiveness Against All-Cause Mortality Following Laboratory-Confirmed Influenza in Older Adults, 2010â€“2011 to 2015â€“2016 Seasons in Ontario, Canada. <i>Clinical Infectious Diseases</i> , 2021, 73, e1191-e1199.	5.8	9
23	Influenza Vaccine Effectiveness in Preventing Hospitalizations in Older Patients With Chronic Obstructive Pulmonary Disease. <i>Journal of Infectious Diseases</i> , 2020, 221, 42-52.	4.0	7
24	Diagnostic Sensitivity of Nasopharyngeal RT-PCR in a Long-Term Care Home Outbreak. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 1570-1572.e1.	2.5	2
25	Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein mutation now documented worldwide. <i>Scientific Reports</i> , 2020, 10, 14031.	3.3	173
26	Paediatric critical illness associated with respiratory infection: a single-centre, retrospective cohort study. <i>BMJ Paediatrics Open</i> , 2020, 4, e000640.	1.4	2
27	Real-time PCR-based SARS-CoV-2 detection in Canadian laboratories. <i>Journal of Clinical Virology</i> , 2020, 128, 104433.	3.1	102
28	Diagnosis and Management of First Case of COVID-19 in Canada: Lessons Applied From SARS-CoV-1. <i>Clinical Infectious Diseases</i> , 2020, 71, 2207-2210.	5.8	113
29	Diagnosing COVID-19: The Disease and Tools for Detection. <i>ACS Nano</i> , 2020, 14, 3822-3835.	14.6	1,360
30	Presence of Flavivirus Antibodies Does Not Lead to a Greater Number of Symptoms in a Small Cohort of Canadian Travelers Infected with Zika Virus. <i>Viruses</i> , 2020, 12, 140.	3.3	2
31	Validation of a Laboratory-Developed Triplex Molecular Assay for Simultaneous Detection of Gastrointestinal Adenovirus and Rotavirus in Stool Specimens. <i>Pathogens</i> , 2020, 9, 326.	2.8	1
32	Influenza Vaccine Does Not Increase the Risk of Coronavirus or Other Noninfluenza Respiratory Viruses: Retrospective Analysis From Canada, 2010â€“2011 to 2016â€“2017. <i>Clinical Infectious Diseases</i> , 2020, 71, 2285-2288.	5.8	32
33	The impact of repeated vaccination using 10-year vaccination history on protection against influenza in older adults: a test-negative design study across the 2010/11 to 2015/16 influenza seasons in Ontario, Canada. <i>Eurosurveillance</i> , 2020, 25, .	7.0	15
34	Interim estimates of 2019/20 vaccine effectiveness during early-season co-circulation of influenza A and B viruses, Canada, February 2020. <i>Eurosurveillance</i> , 2020, 25, .	7.0	28
35	Surveillance of persons who tested negative for COVID-19 in Ontario, January 22â€“February 22, 2020. <i>Canada Communicable Disease Report</i> , 2020, 46, 150-154.	1.3	2
36	Can routinely collected laboratory and health administrative data be used to assess influenza vaccine effectiveness? Assessing the validity of the Flu and Other Respiratory Viruses Research (FOREVER) Cohort. <i>Vaccine</i> , 2019, 37, 4392-4400.	3.8	28

#	ARTICLE	IF	CITATIONS
37	Influenza Vaccine Effectiveness Among Patients With Cancer: A Population-Based Study Using Health Administrative and Laboratory Testing Data From Ontario, Canada. <i>Journal of Clinical Oncology</i> , 2019, 37, 2795-2804.	1.6	41
38	Assessment of population immunity to measles in Ontario, Canada: a Canadian Immunization Research Network (CIRN) study. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2856-2864.	3.3	8
39	Influenza virus RNA recovered from droplets and droplet nuclei emitted by adults in an acute care setting. <i>Journal of Occupational and Environmental Hygiene</i> , 2019, 16, 341-348.	1.0	19
40	Equity and impact: Ontario's infant rotavirus immunization program five years following implementation. A population-based cohort study. <i>Vaccine</i> , 2019, 37, 2408-2414.	3.8	6
41	Characteristics and Outcomes of Young Children Hospitalized With Laboratory-confirmed Influenza or Respiratory Syncytial Virus in Ontario, Canada, 2009-2014. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 362-369.	2.0	11
42	The direct healthcare costs attributable to West Nile virus illness in Ontario, Canada: a population-based cohort study using laboratory and health administrative data. <i>BMC Infectious Diseases</i> , 2019, 19, 1059.	2.9	2
43	Effects of Absolute Humidity, Relative Humidity, Temperature, and Wind Speed on Influenza Activity in Toronto, Ontario, Canada. <i>Applied and Environmental Microbiology</i> , 2019, 85, .	3.1	76
44	Genetic characterization of human metapneumovirus identified through community and facility-based surveillance of infants in Dhaka, Bangladesh. <i>Journal of Medical Virology</i> , 2019, 91, 549-554.	5.0	7
45	Vaccine Effectiveness Against Lineage-matched and -mismatched Influenza B Viruses Across 8 Seasons in Canada, 2010-2011 to 2017-2018. <i>Clinical Infectious Diseases</i> , 2019, 68, 1754-1757.	5.8	46
46	Cost-effectiveness of measles control during elimination in Ontario, Canada, 2015. <i>Eurosurveillance</i> , 2019, 24, .	7.0	3
47	Children under 10 years of age were more affected by the 2018/19 influenza A(H1N1)pdm09 epidemic in Canada: a possible cohort effect following the 2009 influenza pandemic. <i>Eurosurveillance</i> , 2019, 24, .	7.0	9
48	Interim estimates of 2018/19 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, January 2019. <i>Eurosurveillance</i> , 2019, 24, .	7.0	57
49	Paradoxical clade- and age-specific vaccine effectiveness during the 2018/19 influenza A(H3N2) epidemic in Canada: potential imprint-regulated effect of vaccine (I-REV). <i>Eurosurveillance</i> , 2019, 24, .	7.0	51
50	Haemophilus parainfluenza bacteremia post-ERCP and cholecystectomy in a pediatric patient: A case report. <i>Jammi</i> , 2019, 4, 182-186.	0.5	3
51	Rotavirus genotypes circulating in Ontario, Canada, before and after implementation of the rotavirus immunization program. <i>Vaccine</i> , 2018, 36, 2033-2040.	3.8	5
52	Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. <i>New England Journal of Medicine</i> , 2018, 378, 345-353.	27.0	821
53	Influenza vaccine effectiveness among cancer patients: A population-based study using health administrative and laboratory testing data from Ontario, Canada. <i>Annals of Oncology</i> , 2018, 29, viii568.	1.2	1
54	Enterovirus D68 in a community hospital: A test-negative case-control study. <i>Jammi</i> , 2018, 3, 8-13.	0.5	0

#	ARTICLE	IF	CITATIONS
55	Laboratory testing and phylogenetic analysis during a mumps outbreak in Ontario, Canada. <i>Virology Journal</i> , 2018, 15, 98.	3.4	10
56	Should Sex Be Considered an Effect Modifier in the Evaluation of Influenza Vaccine Effectiveness?. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy211.	0.9	21
57	Canada-Wide Epidemic of emm74 Group A Streptococcus Invasive Disease. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy085.	0.9	15
58	Serotype distribution of invasive Streptococcus pneumoniae in adults 65 years of age and over after the introduction of childhood 13-valent pneumococcal conjugate vaccination programs in Canada, 2010–2016. <i>Vaccine</i> , 2018, 36, 4701-4707.	3.8	23
59	Use of Genome Sequencing to Define Institutional Influenza Outbreaks, Toronto, Ontario, Canada, 2014–15. <i>Emerging Infectious Diseases</i> , 2018, 24, 492-497.	4.3	22
60	Molecular characterization of predominant Streptococcus pneumoniae serotypes causing invasive infections in Canada: the SAVE study, 2011–15. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, vii20-vii31.	3.0	27
61	Limitations of administrative data to identify measles cases in Ontario, Canada: a cautionary tale. <i>Canadian Journal of Public Health</i> , 2018, 109, 3-7.	2.3	1
62	Zika virus infection in a pregnant Canadian traveler with congenital fetal malformations noted by ultrasonography at 14-weeks gestation. <i>Tropical Diseases, Travel Medicine and Vaccines</i> , 2018, 4, 2.	2.2	5
63	Targeting Intracellular Ion Homeostasis for the Control of Respiratory Syncytial Virus. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2018, 59, 733-744.	2.9	28
64	Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018. <i>Eurosurveillance</i> , 2018, 23, .	7.0	79
65	Pre-and post-pandemic trends in antiviral use in hospitalized patients with laboratory-confirmed influenza: 2004/05–2013/14, Toronto, Canada. <i>Antiviral Research</i> , 2017, 140, 158-163.	4.1	6
66	Evaluation of Euroimmun Anti-Zika Virus IgM and IgG Enzyme-Linked Immunosorbent Assays for Zika Virus Serologic Testing. <i>Journal of Clinical Microbiology</i> , 2017, 55, 2462-2471.	3.9	88
67	Detecting and quantifying influenza virus with self-versus investigator-collected mid-turbinate nasal swabs. <i>Journal of Medical Virology</i> , 2017, 89, 1295-1299.	5.0	7
68	Evaluation of Altona Diagnostics RealStar Zika Virus Reverse Transcription-PCR Test Kit for Zika Virus PCR Testing. <i>Journal of Clinical Microbiology</i> , 2017, 55, 1576-1584.	3.9	28
69	Beyond Antigenic Match: Possible Agent-Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During the 2015–2016 Season in Canada. <i>Journal of Infectious Diseases</i> , 2017, 216, 1487-1500.	4.0	85
70	Lineage-specific epitope profiles for H5 pre-pandemic vaccine selection and evaluation. <i>Influenza and Other Respiratory Viruses</i> , 2017, 11, 445-456.	3.4	7
71	Age-Related Differences in Influenza B Infection by Lineage in a Community-Based Sentinel System, 2010–2011 to 2015–2016, Canada. <i>Journal of Infectious Diseases</i> , 2017, 216, 697-702.	4.0	29
72	Influenza and rhinovirus viral load and disease severity in upper respiratory tract infections. <i>Journal of Clinical Virology</i> , 2017, 86, 14-19.	3.1	80

#	ARTICLE	IF	CITATIONS
73	Serial Vaccination and the Antigenic Distance Hypothesis: Effects on Influenza Vaccine Effectiveness During A(H3N2) Epidemics in Canada, 2010â€“2011 to 2014â€“2015. <i>Journal of Infectious Diseases</i> , 2017, 215, 1059-1099.	4.0	126
74	Molecular Investigation of an Ontario Mumps Outbreak using Whole Genome Sequencing. <i>Open Forum Infectious Diseases</i> , 2017, 4, S359-S359.	0.9	0
75	Global Distribution and Evolutionary History of Enterovirus D68, with Emphasis on the 2014 Outbreak in Ontario, Canada. <i>Frontiers in Microbiology</i> , 2017, 8, 257.	3.5	23
76	Phylogenetic analysis of emergent <i>Streptococcus pneumoniae</i> serotype 22F causing invasive pneumococcal disease using whole genome sequencing. <i>PLoS ONE</i> , 2017, 12, e0178040.	2.5	21
77	The utility of measles and rubella IgM serology in an elimination setting, Ontario, Canada, 2009â€“2014. <i>PLoS ONE</i> , 2017, 12, e0181172.	2.5	17
78	Vaccine effectiveness against laboratory-confirmed influenza hospitalizations among young children during the 2010-11 to 2013-14 influenza seasons in Ontario, Canada. <i>PLoS ONE</i> , 2017, 12, e0187834.	2.5	27
79	Seasonal Influenza Forecasting in Real Time Using the Incidence Decay With Exponential Adjustment Model. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx166.	0.9	6
80	Measles Outbreak with Unique Virus Genotyping, Ontario, Canada, 2015. <i>Emerging Infectious Diseases</i> , 2017, 23, 1063-1069.	4.3	23
81	Measuring influenza RNA quantity after prolonged storage or multiple freeze/thaw cycles. <i>Journal of Virological Methods</i> , 2017, 247, 45-50.	2.1	16
82	Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017. <i>Eurosurveillance</i> , 2017, 22, .	7.0	56
83	Spectrum of Viral Pathogens in Blood of Malaria-Free Ill Travelers Returning to Canada. <i>Emerging Infectious Diseases</i> , 2016, 22, 854-861.	4.3	5
84	Whole-genome Sequencing for Surveillance of Invasive Pneumococcal Diseases in Ontario, Canada: Rapid Prediction of Genotype, Antibiotic Resistance and Characterization of Emerging Serotype 22F. <i>Frontiers in Microbiology</i> , 2016, 7, 2099.	3.5	7
85	Evaluation and Comparison of Multiple Test Methods, Including Real-time PCR, for <i>Legionella</i> Detection in Clinical Specimens. <i>Frontiers in Public Health</i> , 2016, 4, 175.	2.7	38
86	Epidemiology of Zika virus, 1947â€“2007. <i>BMJ Global Health</i> , 2016, 1, e000087.	4.7	50
87	A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014â€“2015 Season. <i>Clinical Infectious Diseases</i> , 2016, 63, 21-32.	5.8	167
88	Population structure and drug resistance patterns of emerging non-PCV-13 <i>Streptococcus pneumoniae</i> serotypes 22F, 15A, and 8 isolated from adults in Ontario, Canada. <i>Infection, Genetics and Evolution</i> , 2016, 42, 1-8.	2.3	17
89	Maternal vitamin D supplementation during pregnancy and lactation to prevent acute respiratory infections in infancy in Dhaka, Bangladesh (MDARI trial): protocol for a prospective cohort study nested within a randomized controlled trial. <i>BMC Pregnancy and Childbirth</i> , 2016, 16, 309.	2.4	20
90	The epidemiology of invasive pneumococcal disease in older adults from 2007 to 2014 in Ontario, Canada: a population-based study. <i>CMAJ Open</i> , 2016, 4, E545-E550.	2.4	18

#	ARTICLE	IF	CITATIONS
91	High Incidence of Invasive Group A Streptococcus Disease Caused by Strains of Uncommon <i>emm</i> Types in Thunder Bay, Ontario, Canada. <i>Journal of Clinical Microbiology</i> , 2016, 54, 83-92.	3.9	55
92	Association of serotype with respiratory presentations of pneumococcal infection, Ontario, Canada, 2003–2011. <i>Vaccine</i> , 2016, 34, 846-853.	3.8	12
93	Interim estimates of 2015/16 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, February 2016. <i>Eurosurveillance</i> , 2016, 21, 30168.	7.0	44
94	Mutations acquired during cell culture isolation may affect antigenic characterisation of influenza A(H3N2) clade 3C.2a viruses. <i>Eurosurveillance</i> , 2016, 21, 30112.	7.0	32
95	Much left to learn about Zika. <i>The Canadian Nurse</i> , 2016, 112, 20.	0.0	0
96	Genetic diversity and evolutionary insights of respiratory syncytial virus A ON1 genotype: global and local transmission dynamics. <i>Scientific Reports</i> , 2015, 5, 14268.	3.3	104
97	Genetic Analysis of Invasive Pneumococcal Isolates from Children in Ontario, Canada, 2007–2012. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 594-598.	2.0	15
98	Human metapneumovirus prevalence and molecular epidemiology in respiratory outbreaks in Ontario, Canada. <i>Journal of Medical Virology</i> , 2015, 87, 269-274.	5.0	18
99	Acute Respiratory Infections in Travelers Returning from MERS-CoV-Affected Areas. <i>Emerging Infectious Diseases</i> , 2015, 21, 1654-1656.	4.3	12
100	Randomized evaluation of live attenuated vs. inactivated influenza vaccines in schools (RELATIVES) pilot study: A cluster randomized trial. <i>Vaccine</i> , 2015, 33, 535-541.	3.8	13
101	Randomized evaluation of live attenuated vs. inactivated influenza vaccines in schools (RELATIVES) cluster randomized trial: Pilot results from a household surveillance study to assess direct and indirect protection from influenza vaccination. <i>Vaccine</i> , 2015, 33, 4910-4915.	3.8	17
102	Detection of Enterovirus D68 in Canadian Laboratories. <i>Journal of Clinical Microbiology</i> , 2015, 53, 1748-1751.	3.9	15
103	Integrated Sentinel Surveillance Linking Genetic, Antigenic, and Epidemiologic Monitoring of Influenza Vaccine-Virus Relatedness and Effectiveness During the 2013–2014 Influenza Season. <i>Journal of Infectious Diseases</i> , 2015, 212, 726-739.	4.0	66
104	Influenza virus emitted by naturally-infected hosts in a healthcare setting. <i>Journal of Clinical Virology</i> , 2015, 73, 105-107.	3.1	8
105	Epidemiology of Enterovirus D68 in Ontario. <i>PLoS ONE</i> , 2015, 10, e0142841.	2.5	15
106	Preexisting CD4+ T-Cell Immunity in Human Population to Avian Influenza H7N9 Virus: Whole Proteome-Wide Immunoinformatics Analyses. <i>PLoS ONE</i> , 2014, 9, e91273.	2.5	12
107	Low 2012–13 Influenza Vaccine Effectiveness Associated with Mutation in the Egg-Adapted H3N2 Vaccine Strain Not Antigenic Drift in Circulating Viruses. <i>PLoS ONE</i> , 2014, 9, e92153.	2.5	347
108	Performance of Rapid Influenza Diagnostic Testing in Outbreak Settings. <i>Journal of Clinical Microbiology</i> , 2014, 52, 4309-4317.	3.9	25

#	ARTICLE	IF	CITATIONS
109	Multiple Influenza A (H3N2) Mutations Conferring Resistance to Neuraminidase Inhibitors in a Bone Marrow Transplant Recipient. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 7188-7197.	3.2	53
110	Influenza A/Subtype and B/Lineage Effectiveness Estimates for the 2011â€“2012 Trivalent Vaccine: Cross-Season and Cross-Lineage Protection With Unchanged Vaccine. <i>Journal of Infectious Diseases</i> , 2014, 210, 126-137.	4.0	106
111	Genetic characterization of seasonal influenza A (H3N2) viruses in Ontario during 2010â€“2011 influenza season: high prevalence of mutations at antigenic sites. <i>Influenza and Other Respiratory Viruses</i> , 2014, 8, 250-257.	3.4	17
112	Coxsackieviruses in Ontario, January 2005 to December 2011. <i>International Journal of Infectious Diseases</i> , 2014, 25, 136-141.	3.3	7
113	Temporal changes in respiratory adenovirus serotypes circulating in the greater Toronto area, Ontario, during December 2008 to April 2010. <i>Virology Journal</i> , 2013, 10, 15.	3.4	19
114	T cell memory to evolutionarily conserved and shared hemagglutinin epitopes of H1N1 viruses: a pilot scale study. <i>BMC Infectious Diseases</i> , 2013, 13, 204.	2.9	15
115	Local public health response to vaccine-associated measles: case report. <i>BMC Public Health</i> , 2013, 13, 269.	2.9	16
116	Have changing pneumococcal vaccination programmes impacted disease in Ontario?. <i>Vaccine</i> , 2013, 31, 2680-2685.	3.8	15
117	Evaluation of 2009 pandemic H1N1 influenza vaccination in adults with lymphoid malignancies receiving chemotherapy or following autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , 2013, 54, 1387-1395.	1.3	17
118	Community-acquired respiratory viruses and coinfection among patients of Ontario sentinel practices, April 2009 to February 2010. <i>Influenza and Other Respiratory Viruses</i> , 2013, 7, 559-566.	3.4	18
119	Variant influenza A (H1N1) virus infection in Canada. <i>Journal of Clinical Virology</i> , 2013, 57, 279-281.	3.1	3
120	Risk Factors for Influenza among Health Care Workers during 2009 Pandemic, Toronto, Ontario, Canada. <i>Emerging Infectious Diseases</i> , 2013, 19, 606-615.	4.3	32
121	Macrolide-Resistant <i>Mycoplasma pneumoniae</i> in Humans, Ontario, Canada, 2010â€“2011. <i>Emerging Infectious Diseases</i> , 2013, 19, .	4.3	49
122	Vaccine Effectiveness Against Laboratory-Confirmed Influenza Hospitalizations Among Elderly Adults During the 2010-2011 Season. <i>Clinical Infectious Diseases</i> , 2013, 57, 820-827.	5.8	54
123	Expression of recombinant HA1 protein for specific detection of influenza A/H1N1/2009 antibodies in human serum. <i>Microbiology and Immunology</i> , 2013, 57, 77-81.	1.4	4
124	Laboratory-Confirmed Influenza B Infection in Immunized Long-Term Care Facility Residents Receiving Oseltamivir Prophylaxis in Ontario. <i>Infection Control and Hospital Epidemiology</i> , 2013, 34, 1225-1228.	1.8	1
125	Optimal number of samples to test for institutional respiratory infection outbreaks in Ontario. <i>Epidemiology and Infection</i> , 2013, 141, 1781-1785.	2.1	1
126	Low Seroconversion after One Dose of AS03-Adjuvanted H1N1 Pandemic Influenza Vaccine in Solid-Organ Transplant Recipients. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2013, 24, e7-e10.	1.9	10

#	ARTICLE	IF	CITATIONS
127	Pandemic H1N1 Influenza Infection and Vaccination in Humans Induces Cross-Protective Antibodies that Target the Hemagglutinin Stem. <i>Frontiers in Immunology</i> , 2012, 3, 87.	4.8	104
128	A Sentinel Platform to Evaluate Influenza Vaccine Effectiveness and New Variant Circulation, Canada 2010â€“2011 Season. <i>Clinical Infectious Diseases</i> , 2012, 55, 332-342.	5.8	106
129	Genetic Variability of Human Respiratory Syncytial Virus A Strains Circulating in Ontario: A Novel Genotype with a 72 Nucleotide G Gene Duplication. <i>PLoS ONE</i> , 2012, 7, e32807.	2.5	265
130	Poor seroprotection but allosensitization after adjuvanted pandemic influenza H1N1 vaccine in kidney transplant recipients. <i>Transplant Infectious Disease</i> , 2012, 14, 575-583.	1.7	35
131	A five-year surveillance study (2007-2011) of invasive pneumococcal disease cases among children of Ontario in Canada. <i>International Journal of Infectious Diseases</i> , 2012, 16, e307-e308.	3.3	0
132	Potential T cell epitopes within swine-origin triple reassortant influenza A (H3N2) variant virus which emerged in 2011: An immunoinformatics study. <i>Vaccine</i> , 2012, 30, 6054-6063.	3.8	8
133	Recovery of Influenza B Virus with the H273Y Point Mutation in the Neuraminidase Active Site from a Human Patient. <i>Journal of Clinical Microbiology</i> , 2012, 50, 2500-2502.	3.9	21
134	Immunogenicity of a half-dose of adjuvanted 2009 pandemic H1N1 influenza vaccine in adults: a prospective cohort study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 591-597.	2.9	1
135	Respiratory viral infections in institutions from late stage of the first and second waves of pandemic influenza A (H1N1) 2009, Ontario, Canada. <i>Influenza and Other Respiratory Viruses</i> , 2012, 6, e11-5.	3.4	6
136	Early post-transplant vaccination with pandemic influenza A/H1N1 vaccine in pediatric heart transplant recipients. <i>Pediatric Transplantation</i> , 2011, 15, 172-175.	1.0	13
137	Analytical performance of norovirus real-time RT-PCR detection protocols in Canadian laboratories. <i>Journal of Clinical Virology</i> , 2011, 50, 109-113.	3.1	17
138	Evaluation of pandemic H1N1 (2009) influenza vaccine in adults with solid tumor and hematological malignancies on active systemic treatment. <i>Journal of Clinical Virology</i> , 2011, 50, 212-216.	3.1	29
139	Neuraminidase-inhibitor resistance testing for pandemic influenza A (H1N1) 2009 in Ontario, Canada. <i>Journal of Clinical Virology</i> , 2011, 50, 257-261.	3.1	15
140	When should a diagnosis of influenza be considered in adults requiring intensive care unit admission? Results of population-based active surveillance in Toronto. <i>Critical Care</i> , 2011, 15, R182.	5.8	18
141	Multidrug-Resistant Pandemic (H1N1) 2009 Infection in Immunocompetent Child. <i>Emerging Infectious Diseases</i> , 2011, 17, 1472-4.	4.3	27
142	Seroprevalence of Pandemic Influenza H1N1 in Ontario from January 2009â€“May 2010. <i>PLoS ONE</i> , 2011, 6, e26427.	2.5	23
143	Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. <i>BMJ: British Medical Journal</i> , 2011, 342, c7297-c7297.	2.3	95
144	Evaluation and Verification of the Seeplex Diarrhea-V ACE Assay for Simultaneous Detection of Adenovirus, Rotavirus, and Norovirus Genogroups I and II in Clinical Stool Specimens. <i>Journal of Clinical Microbiology</i> , 2011, 49, 3154-3162.	3.9	50

#	ARTICLE	IF	CITATIONS
145	An assessment of mumps vaccine effectiveness by dose during an outbreak in Canada. <i>Cmaj</i> , 2011, 183, 1014-1020.	2.0	71
146	Detection of an Influenza B Virus Strain with Reduced Susceptibility to Neuraminidase Inhibitor Drugs. <i>Journal of Clinical Microbiology</i> , 2011, 49, 4020-4021.	3.9	15
147	Humoral and Cell-Mediated Immunity to Pandemic H1N1 Influenza in a Canadian Cohort One Year Post-Pandemic: Implications for Vaccination. <i>PLoS ONE</i> , 2011, 6, e28063.	2.5	38
148	Long Term Immune Responses to Pandemic Influenza A/H1N1 Infection in Solid Organ Transplant Recipients. <i>PLoS ONE</i> , 2011, 6, e28627.	2.5	16
149	SEVERE HUMAN RHINOVIRUS OUTBREAK ASSOCIATED WITH FATALITIES IN A LONG-TERM CARE FACILITY IN ONTARIO, CANADA. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 2036-2038.	2.6	16
150	High Prevalence of Asymptomatic Bocavirus in Daycare: Is Otitis Media a Confounder?. <i>Journal of Infectious Diseases</i> , 2010, 202, 1617-1617.	4.0	5
151	Rhinovirus Outbreaks in Long-term Care Facilities, Ontario, Canada. <i>Emerging Infectious Diseases</i> , 2010, 16, 1463-1465.	4.3	36
152	Transmission of Influenza A Pandemic (H1N1) 2009 Virus in a Long-Term Care Facility in Ontario, Canada. <i>Infection Control and Hospital Epidemiology</i> , 2010, 31, 1300-1302.	1.8	2
153	Respiratory Infection in Institutions during Early Stages of Pandemic (H1N1) 2009, Canada. <i>Emerging Infectious Diseases</i> , 2009, 15, 2001-2003.	4.3	9
154	Older Age and a Reduced Likelihood of 2009 H1N1 Virus Infection. <i>New England Journal of Medicine</i> , 2009, 361, 2000-2001.	27.0	92
155	Multiplex PCR tests sentinel the appearance of pandemic influenza viruses including H1N1 swine influenza. <i>Journal of Clinical Virology</i> , 2009, 45, 200-202.	3.1	36
156	Clinical features, epidemiology, antimicrobial resistance, and exotoxin genes (including that of Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 31 (GS-MRSA) isolated at a paediatric teaching hospital in New South Wales, Australia. <i>Pathology</i> , 2008, 40, 64-71.	0.6	15
157	Cellulitis in childhood invasive pneumococcal disease: A population-based study. <i>Journal of Paediatrics and Child Health</i> , 2006, 42, 354-358.	0.8	3